Literature DB >> 12565174

Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human breast carcinoma.

Hisashi Saji1, Masakazu Toi, Shigehira Saji, Morio Koike, Kimitoshi Kohno, Michihiko Kuwano.   

Abstract

Drug resistance is a common clinical problem in cancer treatment. The overexpression of P-glycoprotein appears to be closely associated with multi-drug resistance to anticancer agents. YB-1 binds to the Y-box in the promoter region of MDR1, which encodes P-glycoprotein. We evaluated the correlation between nuclear YB-1 and P-glycoprotein expression and other molecules, such as hormonal receptors, angiogenic factors, immune factors, and methalloprotease in 63 human breast cancers. Nuclear YB-1 expression had a significant correlation with P-glycoprotein and PgR expression, and also with CD68 grade, concerning accumulation of tumor associated macrophages. This series did not demonstrate P-glycoprotein and nuclear YB-1 expression might be one of the useful prognostic marker of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12565174     DOI: 10.1016/s0304-3835(02)00590-6

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

1.  Prognostic role of YB-1 expression in breast cancer: a meta-analysis.

Authors:  Xu Wang; Xiao-Bo Guo; Xiao-Chun Shen; Hao Zhou; Dan-Wei Wan; Xiao-Feng Xue; Ye Han; Bin Yuan; Jin Zhou; Hong Zhao; Qiao-Ming Zhi; Yu-Ting Kuang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  JC virus-induced Progressive Multifocal Leukoencephalopathy.

Authors:  A Sami Saribas; Ahmet Ozdemir; Cathy Lam; Mahmut Safak
Journal:  Future Virol       Date:  2010-05       Impact factor: 1.831

3.  Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85.

Authors:  Elena V Batrakova; David L Kelly; Shu Li; Yili Li; Zhihui Yang; Li Xiao; Daria Y Alakhova; Simon Sherman; Valery Yu Alakhov; Alexander V Kabanov
Journal:  Mol Pharm       Date:  2006 Mar-Apr       Impact factor: 4.939

Review 4.  ATP-binding cassette efflux transporters in human placenta.

Authors:  Zhanglin Ni; Qingcheng Mao
Journal:  Curr Pharm Biotechnol       Date:  2011-04       Impact factor: 2.837

Review 5.  [YB-1 as a potential target in cancer therapy].

Authors:  H Lage; P Surowiak; P S Holm
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

6.  Significance of the Y-box proteins in human cancers.

Authors:  Ken Matsumoto; Boon-Huat Bay
Journal:  J Mol Genet Med       Date:  2005-08-03

7.  Cellular localization of Y-box binding protein 1 in brain tissue of rats, macaques, and humans.

Authors:  Bernadette Unkrüer; Anton Pekcec; Christina Fuest; Andrea Wehmeyer; Maria S Balda; Anja Horn; Wolfgang Baumgärtner; Heidrun Potschka
Journal:  BMC Neurosci       Date:  2009-03-26       Impact factor: 3.288

8.  Nuclear detection of Y-box protein-1 (YB-1) closely associates with progesterone receptor negativity and is a strong adverse survival factor in human breast cancer.

Authors:  Edgar Dahl; Abdelaziz En-Nia; Frank Wiesmann; Renate Krings; Sonja Djudjaj; Elisabeth Breuer; Thomas Fuchs; Peter J Wild; Arndt Hartmann; Sandra E Dunn; Peter R Mertens
Journal:  BMC Cancer       Date:  2009-11-24       Impact factor: 4.430

9.  Development of a Chemiluminescence Immunoassay for Serum YB-1 and its Clinical Application as a Potential Diagnostic Marker for Hepatocellular Carcinoma.

Authors:  Li Pu; Shi Jing; Guo Bianqin; Liu Ping; Liang Qindong; Liu Chenggui; Cheng Feng; Kuang Wenbin; Wang Qin; Dong Jinyu; Xia Qianfeng; Liu Yu; Tu Zhiguang
Journal:  Hepat Mon       Date:  2013-07-03       Impact factor: 0.660

10.  Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-κB and MAPK/ERK mediated YB-1 activity in A2780/T cells.

Authors:  Bo-xin Zhao; Ya-bin Sun; Sheng-qi Wang; Lian Duan; Qi-lu Huo; Fei Ren; Guo-feng Li
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.